Medication info

Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20/12.5 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Daiichi Sankyo Korea Co., Ltd.
Appearance
Round, yellowish-orange film-coated tablets
Packaging
28 tablets (14 tablets/PTP X 2)/carton
Approval status
Approval withdrawn

MFDS item code 201305039 · Approved 2013.02.15 · Insurance code 680900140

This product's status changed to Approval withdrawn on 2025.12.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted individually. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, with or without food. Adjust the dose at intervals of 2~4 weeks based on the patient's blood pressure response. When olmesartan medoxomil is added to treatment or patients are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide) from a high-dose hydrochlorothiazide monotherapy, or in patients with volume depletion or hyponatremia, a marked reduction in blood pressure may occur. In this case, reduce the hydrochlorothiazide dose to 12.5mg before adding olmesartan medoxomil. <Elderly patients> In elderly patients, start at the lowest dose and use caution when adjusting the dose, taking into account renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is usually administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This medicine (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, because loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> There is no experience with use in patients with hepatic impairment; use of this medicine is not recommended.
Child dose
<Children> Safety and efficacy in children have not been established.

Ingredients

Importer
Daiichi Sankyo Korea Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication combines Olmesartan Medoxomil and Hydrochlorothiazide and is used to effectively lower blood pressure in patients with essential hypertension who find it difficult to control blood pressure with monotherapy. The two components act together to dilate blood vessels and help the body eliminate excess salt and water, thereby controlling blood pressure steadily. This helps reduce the risk of cardiovascular complications and improves the patient's health. Regular use will be of great help in managing hypertension.

How to take

Adult dose

Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted individually. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, with or without food. Adjust the dose at intervals of 2~4 weeks based on the patient's blood pressure response. When olmesartan medoxomil is added to treatment or patients are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide) from a high-dose hydrochlorothiazide monotherapy, or in patients with volume depletion or hyponatremia, a marked reduction in blood pressure may occur. In this case, reduce the hydrochlorothiazide dose to 12.5mg before adding olmesartan medoxomil. <Elderly patients> In elderly patients, start at the lowest dose and use caution when adjusting the dose, taking into account renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is usually administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This medicine (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, because loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> There is no experience with use in patients with hepatic impairment; use of this medicine is not recommended.

Child dose

<Children> Safety and efficacy in children have not been established.

Precautions

This medication can cause serious harm or death to the fetus and newborn during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Patients who have allergies to the ingredients in this medication or hypersensitivity to certain diuretics, those with acute kidney disease or severe liver disease, and patients with certain genetic metabolic disorders should not take this medication. Patients with low blood volume or low sodium may experience hypotension, so their condition should be checked carefully before taking the medication, and appropriate measures should be taken if necessary. Patients with impaired kidney function, kidney transplant patients, renal artery stenosis patients, liver disease patients, etc. should use caution as their kidney or liver function may be affected by this medication. This medication can affect electrolyte balance, especially potassium, sodium, calcium, and magnesium levels, so regular blood tests are necessary. Various side effects, including dizziness, nausea, headaches, rashes, and low blood pressure may occur; if symptoms are severe, consultation with healthcare professionals is advised. This medication may interact with other antihypertensives, diuretics, lithium, non-steroidal anti-inflammatory drugs, etc., so patients must inform their doctors about any other medications they are taking. Pregnant or breastfeeding women should decide whether to take this medication based on their doctor’s instructions as it may affect the fetus or infant. The elderly should start at the lowest dose due to the potential for decreased kidney and liver function and should take the medication cautiously. In case of overdose, symptoms such as hypotension, electrolyte abnormalities, and dehydration may appear, and immediate medical attention should be sought for appropriate treatment. During treatment with this medication, care must be taken to avoid excessive exposure to sunlight, and if any skin abnormalities occur, consultation with a doctor should be sought immediately.

Side effects

Nausea, hyperuricemia, dizziness, upper respiratory tract infection, headache, urinary tract infection, chest pain, back pain, peripheral edema, vertigo, abdominal pain, indigestion, gastroenteritis, diarrhea, elevated AST, elevated GGT, elevated ALT, hyperlipidemia, elevated creatine phosphokinase, hyperglycemia, cough, rash, hematuria, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, hyperkalemia, rhabdomyolysis, acute renal failure, increased serum creatinine, hair loss, itching, hives, palpitations, fatigue, drowsiness, emotional blunting, restlessness, interstitial pneumonia, pulmonary edema, acute respiratory distress syndrome, orthostatic hypotension, arrhythmia, transient visual blurriness, jaundice, hepatitis, acute cholecystitis, necrotizing vasculitis, interstitial pneumonia, dyspnea, facial flushing, photosensitivity, anaphylaxis, interstitial pneumonia, renal impairment, malaise, nasal congestion, erectile dysfunction, exacerbation of systemic lupus erythematosus, muscle cramps, sensory disturbances, weakness, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, thrombocytopenia, leukopenia, aplastic anemia, hemolytic anemia, purpura, loss of appetite, polydipsia, abdominal discomfort, constipation, abdominal colic, pancreatitis, jaundice, sialadenitis, dry mouth, abnormal liver function tests, chronic malabsorption syndrome, autoimmune hepatitis, elevated blood pressure, epistaxis, asthma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 and 25 degrees Celsius to preserve the effectiveness and safety of the medication over time.

Appearance and packaging

Appearance

Round, yellowish-orange film-coated tablets

Package unit

28 tablets (14 tablets/PTP X 2)/carton

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.